Excelerate Energy Announces Second Quarter 2023 Earnings Conference Call Date
Get Alerts EE Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.9%
Revenue Growth %: +65.2%
Join SI Premium – FREE
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Excelerate Energy, Inc. (NYSE: EE) (the “Company” or “Excelerate”) will release its second quarter 2023 results on Wednesday, August 9, 2023, following the close of U.S. financial markets. The earnings release and presentation for the second quarter 2023 results will be available on the investor page of the Company’s website at www.excelerateenergy.com.
On Thursday, August 10, 2023, the Company’s management team will host a conference call for analysts and investors at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). The call will also be webcast live at www.excelerateenergy.com. An archived replay of the call and a copy of the presentation will be on the website following the call.
About Excelerate Energy:
Excelerate Energy, Inc. is a U.S.-based LNG company located in The Woodlands, Texas. Excelerate is changing the way the world accesses cleaner forms of energy by providing integrated services along the LNG value chain with the objective of delivering rapid-to-market and reliable LNG solutions to customers. The Company offers a full range of flexible regasification services from FSRUs to infrastructure development to LNG supply. Excelerate has offices in Abu Dhabi, Antwerp, Boston, Buenos Aires, Chattogram, Dhaka, Doha, Dubai, Helsinki, Manila, Rio de Janeiro, Singapore, and Washington, DC. For more information, please visit www.excelerateenergy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711377604/en/
Investors:
Craig Hicks
Excelerate Energy
[email protected]
Media:
Stephen Pettibone / Frances Jeter
FGS Global
[email protected]
or
[email protected]
Source: Excelerate Energy, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RHI Magnesita 2026 Half Year Results: Consistent Self-help Delivery and Strong Steel Business Performance Delivers 42% Adj. EBITA Growth on Constant Currency Basis
- Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
- Alverum Reviews: What Makes Alverum Trading Platform Stand Out?
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share